Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of oral sirolimus (NPC-12K) in systemic sclerosis with refractory digital ulcers
jRCT2071220063Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in systemic sclerosis (SSc) and digital ulcer (DU) comparing NPC-12K (sirolimus) arm with Placebo arm (2 arms). Primary endpoint: Suspected adverse reaction rate. Started Feb 2023; status: completed.
02
Drugs
sirolimus
03
Conditions
systemic sclerosis (SSc)digital ulcer (DU)
Beyond the preview
Go deeper on jRCT2071220063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220063.